Racecadotril
A07X - Other antidiarrheal agents
ATC A07XA04
Small molecule
Prodrug
Natural product
Active form: Thiorphan.
JFDA label: Hidrasec Infant 10mg
Mechanism of Action
Inhibitor of Neprilysin — Neprilysin inhibitor
| Target | Action | Gene / class |
|---|---|---|
| Neprilysin efficacy | INHIBITOR | MME |
Indications
Off-label
- Diarrhea
- Diarrhea, Infantile
Pregnancy & Lactation
Lactation
No Data
Hale L3
Until more data become available, racecadotril should be used with caution while nursing a newborn or preterm infant.
Chemistry & Properties
| Formula | C21H23NO4S |
|---|---|
| Molecular weight | 385.49 g/mol |
| IUPAC name | benzyl 2-[[2-(acetylsulfanylmethyl)-3-phenylpropanoyl]amino]acetate |
| CAS | 81110-73-8 |
| PubChem CID | 107751 |
| InChIKey | ODUOJXZPIYUATO-UHFFFAOYSA-N |
| logP | 2.98 (XLogP 3.3) |
| Polar surface area | 72.47 Ų |
| H-bond acceptors / donors | 5 / 1 |
| Drug-likeness (QED) | 0.67 |
| Lipinski violations | 0 |
SMILES
CC(=O)SCC(Cc1ccccc1)C(=O)NCC(=O)OCc1ccccc1Biology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 35.0% |
|---|---|
| Half-life | 0.324 h |
| Volume of distribution | 0.471 L/kg |
| Protein binding | 92.7% |
| BBB penetrant | Yes |
Enzyme interactions
| Enzyme | Role | Detail |
|---|---|---|
| CYP1A2 | Inhibitor | — |
| CYP1A2 | Substrate | — |
| CYP2B6 | Inhibitor | — |
| CYP2C19 | Inhibitor | — |
| CYP2C8 | Inhibitor | — |
| CYP2C9 | Inhibitor | — |
| CYP2D6 | Inhibitor | — |
| CYP3A4 | Inhibitor | — |
| CYP3A4 | Substrate | — |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (3)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|---|---|---|---|
| Hidrasec | Sachet 30 mg | 16 sachet | Sukhtian Group | 3.540 |
| Hidrasec | Capsule 100 mg | 10 cap | Sukhtian Group | 3.680 |
| Hidrasec Infant | Sachet 10 mg | 16 sachet | Sukhtian Group | 6.850 |